Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
- clonoSEQ test featured in 30 scientific presentations including 14 oral presentations, demonstrating strong clinical adoption
- Multiple large-scale phase 3 trials validating clonoSEQ's utility in guiding treatment decisions
- Data shows clonoSEQ effectively measures treatment efficacy across multiple blood cancer types
- Growing evidence supporting clonoSEQ's role in both clinical care and drug development
- None.
Insights
Adaptive's clonoSEQ MRD test featured in 30 presentations at major oncology conferences, validating its clinical utility in blood cancer management.
Adaptive Biotechnologies' announcement that its clonoSEQ measurable residual disease (MRD) test will be featured in 30 scientific presentations at ASCO and EHA represents significant clinical validation for this diagnostic platform. The breadth of data being presented - including 14 oral presentations across multiple blood cancer types - underscores growing clinical adoption and scientific recognition.
The most compelling data comes from two Phase 3 trials (MIDAS and PERSEUS) that demonstrate how clonoSEQ MRD assessment is being used to guide treatment decisions in multiple myeloma. The MIDAS study with 718 patients specifically shows how MRD status is directing therapy post-induction, while PERSEUS with 709 patients reports on sustained MRD negativity's impact on progression-free survival.
The VENETOSTOP study in CLL particularly stands out as it demonstrates how MRD status can be used to potentially shorten venetoclax-based therapy duration - a development that could reduce treatment burden and costs while maintaining efficacy.
Multiple studies also show clonoSEQ being used to evaluate novel quadruplet regimens in multiple myeloma, including combinations with isatuximab, daratumumab, and belantamab mafodotin. These studies consistently report higher MRD negativity rates with these intensive regimens, which correlates with improved clinical outcomes.
The diversity of studies using clonoSEQ across different blood cancers (multiple myeloma, CLL, B-ALL, follicular lymphoma, and mantle cell lymphoma) demonstrates broad utility and acceptance of this testing platform. The presence of clonoSEQ data in trials evaluating cutting-edge therapies including CAR-T treatments further solidifies its position as an essential tool for assessing treatment efficacy in hematologic malignancies.
From a commercial perspective, this extensive scientific visibility at major medical conferences strengthens Adaptive's market position and supports further clinical adoption of clonoSEQ testing. As more treatment protocols incorporate MRD assessment, Adaptive stands to benefit from increasing test volumes and broader reimbursement coverage.
30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancers
SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 30 presentations, including a total of 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago and the European Hematology Association (EHA) Congress taking place June 12-15 in Milan. These presentations include notable new data supporting the clinical actionability of clonoSEQ in both multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).
"The breadth of new MRD evidence being shared across various blood cancer types at ASCO and EHA this year highlights the transformative impact MRD is having on clinical care and drug development," said Susan Bobulsky, Chief Commercial Officer, MRD, Adaptive Biotechnologies. "These data presentations are a testament to the central role that clonoSEQ MRD testing now plays in clinical management and drug development across lymphoid cancers, particularly when combined with several clonoSEQ data presentations in diffuse large B-cell lymphoma (DLBCL) anticipated at the 18th International Conference on Malignant Lymphoma (iCML) on June 17-21, 2025 in Lugano, Switzerland."
Selected presentations include:
Data advancing the clinical actionability of clonoSEQ MRD testing
- Results from MIDAS, a phase 3 randomized study of 718 transplant-eligible, newly diagnosed multiple myeloma (NDMM) patients, demonstrate the use of MRD status to guide therapy post-induction. (ASCO Abstract 7500, June 3, 9:45-9:57 a.m. CDT, S100bc, McCormick Place Convention Center)
- Interim data from ADVANCE, a phase 2 randomized study of 306 transplant-eligible patients with NDMM shows the impact of MRD-guided assessments post-induction (ASCO Abstract 7503, June 3, 10:21-10:33 a.m. CDT, S100bc, McCormick Place Convention Center)
- Interim results from VENETOSTOP, a phase 2 study of 66 CLL patients, report the use of MRD status to shorten duration of venetoclax-based therapy. (EHA Abstract PS1568, June 14, 6:30 p.m. CEST, Poster Hall, Milano Convention Centre)
Studies utilizing clonoSEQ MRD assessment as a critical indicator of quadruplet regimen efficacy in multiple myeloma
- Results from the phase 3 IsKia study of 151 transplant-eligible NDMM patients demonstrates increased rates of sustained MRD negativity at 10-6 with isatuximab plus carfilzomib, lenalidomide, and dexamethasone. (ASCO Abstract 7502, June 3, 10:09-10:21 a.m. CDT, S100bc, McCormick Place Convention Center)
- Follow-up data from PERSEUS, a phase 3 trial of 709 transplant-eligible patients with NDMM reports the impact of sustained MRD negativity status on progression free survival (PFS) with subcutaneous daratumumab plus bortezomib, lenalidomide and dexamethasone (D-VRd) induction and DR maintenance. (ASCO Abstract 7501, June 3, 9:57-10:09 a.m. CDT, S100bc, McCormick Place Convention Center)
- Results from DREAMM-8, a Phase 3 study in 302 patients with relapsed or refractory multiple myeloma, found superior PFS and higher MRD negativity rates in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) as compared to standard-of-care pomalidomide, bortezomib, and dexamethasone (PVd). (ASCO Abstract 7515, June 2, 9:00-9:06 a.m. CDT E450b, McCormick Place Convention Center)
Data to be presented at ASCO:
| Presentation Type and Number | Title | Presentation Timing |
| B-Cell Acute Lymphoblastic Leukemia | ||
| Poster Presentation 6540 | Initial results from a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) for adults with newly-diagnosed (ND) Philadelphia chromosome negative (Ph-) B lymphoblastic leukemia (B-ALL) | Sunday, June 1 9 a.m.-12 p.m. CDT |
| Poster Presentation 6543 | Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute lymphoblastic leukemia | Sunday, June 1 9 a.m.-12 p.m. CDT |
| Multiple Myeloma | ||
| Oral Presentation 7500* | MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial | Tuesday, June 3 9:45-9:57 a.m. CDT |
| Oral Presentation 7501 | Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial | Tuesday, June 3 9:57-10:09 a.m. CDT |
| Oral Presentation 7502 | Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial) | Tuesday, June 3 10:09-10:21 a.m. CDT |
| Oral Presentation 7503* | Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial | Tuesday, June 3 10:21-10:33 a.m. CDT |
| Oral Presentation 7507* | Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM) | Tuesday, June 3 11:57 a.m.-12:09 p.m. CDT |
| Oral Presentation 7515 | Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial | Monday, June 2 9-9:06 a.m. CDT |
| Oral Presentation 7516 | Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study | Monday, June 2 9:06-9:12 a.m. CDT |
| ASCO Oral Presentation 7517* | Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ study | Monday, June 2 9:12-9:18 a.m. CDT |
| Poster Presentation 7529 | Daratumumab + bortezomib, lenalidomide, and dexamethasone (DVRd) vs VRd in transplant-ineligible (TIE)/transplant-deferred (TD) newly diagnosed multiple myeloma (NDMM): Phase 3 CEPHEUS trial cytogenetic subgroup analysis | Sunday, June 1 9 a.m.-12 p.m. CDT |
| Poster Presentation 7535 | Carfilzomib, lenalidomide, and dexamethasone (KRd) as maintenance therapy after autologous stem-cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (NDMM) | Sunday, June 1 9 a.m.-12 p.m. CDT |
| ASCO Poster Presentation 7551* | Positron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysis | Sunday, June 1 9 a.m.-12 p.m. CDT |
Data to be presented at EHA:
| Presentation Type and Number | Title | Presentation Timing |
| B-Cell Acute Lymphoblastic Leukemia | ||
| Oral Presentation S112 | Safety and efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) b-cell acute lymphoblastic leukemia (B-ALL): results from a phase 1/2 dose expansion study | Sunday, June 15 11:30-11:45 a.m. CEST |
| Oral Presentation S117 | Safety and efficacy of AZD0486 in adolescent and adult patients with relapsed or refractory b-cell acute lymphoblastic leukemia: early results from the phase 1/2 SYRUS study | Friday, June 13 5:30-5:45 p.m. CEST |
| Poster Presentation PF372 | Donor-derived, allogeneic CD19/CD22-CAR T cells with myeloablative graft-engineered Allo-HCT for high-risk B-ALL | Friday, June 13 6:30 p.m. CEST |
| Chronic Lymphocytic Leukemia | ||
| Poster Presentation PF575 | Preliminary results of the ongoing multicenter, phase 2 study of retreatment with venetoclax plus obinutuzumab (ReVenG) in patients with recurrent chronic lymphocytic leukemia (CLL) | Friday, June 13 6:30 p.m. CEST |
| Poster Presentation PS1568 | Using minimal residual disease status to guide venetoclax treatment duration in patients with chronic lymphocytic leukemia: interim results from the phase II VENETOSTOP study | Saturday, June 14 6:30 p.m. CEST |
| Follicular Lymphoma | ||
| Poster Presentation PF881 | Epcoritamab monotherapy demonstrates deep and durable responses at 3-year follow-up in patients with relapsed/refractory follicular lymphoma | Friday, June 13 6:30 p.m. CEST |
| Poster Presentation PS2150 | 4-year update of phase 2 ELARA trial: clinical outcomes of tisagenlecleucel in patients (pts) with high-risk relapsed/refractory follicular lymphoma (R/R FL) | Saturday, June 14 6:30 p.m. CEST |
| Mantle Cell Lymphoma | ||
| Poster Presentation PF882 | Minimal residual disease with bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: results from the phase 3 ECHO trial | Friday, June 13 6:30 p.m. CEST |
| Multiple Myeloma | ||
| Oral Presentation S201 | Phase 2 registrational study of anitocabtagene autoleucel for relapsed and/or refractory multiple myeloma (RRMM): updated results from IMMAGINE-1 | Saturday, June 14 5:15-5:30 p.m. CEST |
| Oral Presentation S205* | Minimal residual disease-driven strategy following isatuximab-carfilzomib-lenalidomide-dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma: Primary endpoints of the phase 3 MIDAS trial | Sunday, June 15 11:00-11:15 a.m. CEST |
| Oral Presentation S207* | A randomized, multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) for the treatment of patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial | Sunday, June 15 11:30-11:45 a.m. CEST |
| Oral Presentation S208* | Analysis of sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial) | Sunday, June 15 11:45 a.m.-12 p.m. CEST |
| Poster Presentation PF727 | Isa-vrd improves outcomes in high-risk (HR) newly diagnosed transplant-ineligible multiple myeloma (NDMM TI) using the IMS/IMWG consensus HR definition: results from the BENEFIT phase 3 trial (IFM 2020-05) | Friday, June 13 6:30 p.m. CEST |
| Poster Presentation PF729* | Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): outcomes in patients with 1q21+ status in the phase 3 IMROZ study | Friday, June 13 6:30 p.m. CEST |
| Poster Presentation PF750 | Isatuximab, bortezomib, lenalidomide, dexamethasone (Isa-VRd) in patients with transplant-ineligible (TI) newly diagnosed myeloma (NDMM) and plasmacytomas: IMROZ subgroup analysis | Friday, June 13 6:30 p.m. CEST |
| Poster Presentation PF754 | Interim analysis of MRD-guided maintenance therapy with belantamab mafodotin and lenalidomide after Auto-HCT in newly diagnosed multiple myeloma | Friday, June 13 6:30 p.m. CEST |
| Poster Presentation PS1722* | Positron emission tomography with computed tomography and minimal residual disease for efficacy assessment in transplant-ineligible newly diagnosed myeloma patients: IMROZ analysis | Saturday, June 14 6:30 p.m. CEST |
*Indicates data to be presented at both ASCO and EHA.
About clonoSEQ
clonoSEQ® is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL.
clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier.
clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request.
To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.
About Adaptive Biotechnologies
Adaptive Biotechnologies ("we" or "our") is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Forward Looking Statements
This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections regarding the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
FAQ
What is the significance of Adaptive Biotechnologies' clonoSEQ test presentations at ASCO and EHA 2025?
How is ADPT's clonoSEQ being used in multiple myeloma treatment?
What are the key findings from the MIDAS phase 3 trial using ADPT's clonoSEQ?
How is Adaptive Biotechnologies' clonoSEQ test being used in chronic lymphocytic leukemia (CLL)?
